Compression of the Dahuang Huangqin Yu Powder veterinary-grade API into oral tablets is process-limited by the bimodal particle-size distribution and hygroscopic character of its flavone glucuronide fraction. Production-scale trials on a 16-station rotary press with 15 mm × 8 mm oblong B-tooling established that direct compression is not robust because the unprocessed API has an angle of repose ranging from 34° to 42° and a tapped density between 0.38 and 0.52 g/cm³ across spray-dried lots. A high-shear wet granulation route is therefore specified. The granulation charge is 30.0 % w/w API, 38.0 % w/w microcrystalline cellulose PH102, 24.5 % w/w lactose monohydrate, 4.0 % w/w crospovidone, 3.0 % w/w povidone K30, 0.5 % w/w colloidal silicon dioxide, and 0.5 % w/w magnesium stearate. Granulation in a 50 L high-shear processor at impeller speed 250 rpm and chopper speed 1500 rpm, with purified water added to 8–12 % w/w of dry mass, yields wet mass that is fluid-bed dried at inlet 60 °C and outlet 35–40 °C to a loss-on-drying endpoint of 1.5–2.0 %. The dried granulate is milled through a 0.8 mm conical screen. Tableting is conducted at 14–18 kN compression force and 35–45 rpm press speed; hardness is controlled to 70–110 N, friability below 0.8 % per Ph. Eur. 2.9.7, and disintegration below 15 min in water at 37 °C per Ph. Eur. 2.9.1. Content uniformity is acceptable only when the granulate is kept below 1.5 % water before compression; above 3.0 % water, sticking and capping occur on the press, and residual moisture above 60 % ambient RH requires pre-drying of the granulate at 40 °C for 4 h before compression. Assay of baicalin and total anthraquinones by HPLC per Ph. Eur. 2.2.29 is used to set release at 90.0–110.0 % label claim for the tablets. The finished tablet presentation is intended for oral administration to swine and ruminants, with monographs for tablets and uniformity of dosage units applied under Ph. Eur. 0478 and Ph. Eur. 2.9.40.

When Does Sterile Filtration Become the Rate-Limiting Step for Injectable Veterinary Botanicals?

Sterile injectable presentations built from this API are constrained by the low aqueous solubility of emodin and rhein at neutral pH, not by the solubility of baicalin. A directly reconstituted veterinary injection cannot be prepared from the raw powder without prior removal of tannins and high-molecular-weight plant residues; these substances cause visible haze, filter blocking, and pyrogenic responses. A purified extract fraction is dissolved at 5.0 % w/v in water-for-injection with 15 % v/v propylene glycol and 0.15 % w/v poloxamer 188; the pH is adjusted to 6.8–7.2 with 0.1 M sodium hydroxide. The bulk solution is passed through 1.0 µm glass-fibre and 0.45 µm polyethersulfone clarifiers before the sterilising-grade 0.22 µm PES capsule. On a 0.6 m² capsule at 1.0 bar, flux remains above 200 L/m²/h only if the pre-filter removal rate is maintained; when the 0.45 µm pre-filter pressure exceeds 0.8 bar, the steriliser flux falls below 80 L/m²/h and the batch must be stopped. Terminal autoclaving at 121 °C for 15 min is applicable only when the pH is held below 7.5; above pH 8.0, baicalin degrades rapidly and the solution darkens. Vials are Type I glass per Ph. Eur. 3.2.1 and are depyrogenated at 250 °C for 45 min. The finished injectable is released only after sterility testing per Ph. Eur. 2.6.1, endotoxin testing per Ph. Eur. 2.6.14, and sub-visible particle enumeration per Ph. Eur. 2.9.19. Tannin content must remain below 0.5 mg/mL, because residual tannins are directly pyrogenic and may interact with tissue proteins. The terminal product is a 100 mL multi-dose vial for cattle and swine.

Solubility trials in 500 L tank mixes at 25 °C show that the unmodified powder settles within 45 min unless a ternary carrier of anhydrous lactose, trisodium citrate, and povidone K30 is used. For drinking-water medication in poultry, the API is diluted to 25.0 % w/w in a water-soluble powder base of 55.0 % w/w anhydrous lactose, 10.0 % w/w trisodium citrate, 5.0 % w/w povidone K30, 3.0 % w/w sodium bicarbonate, and 2.0 % w/w citric acid; the blend is mixed in a 400 L V-blender for 15 min at 12 rpm, then packed into foil-lined sachets at ambient humidity below 35 % RH. When reconstituted at 1–2 g/L, the citrate-bicarbonate pair holds pH at 7.5–8.0, which increases baicalin solubility while leaving anthraquinone aglycones as a fine suspensoid; continuous agitation is required because anthraquinones settle after 24 h without stirring. Hard water above 300 mg/L as CaCO₃ reduces baicalin recovery by approximately 10–15 % because calcium ions complex with the glucuronide; water softeners or chelating agents are needed in such supply lines. Microbiological acceptance follows the harmonised oral powder monograph limits: total aerobic microbial count below 10³ CFU/g, and absence of specified micro-organisms per Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13. The terminal presentation is a water-soluble powder sachet for in-feed or in-water administration to poultry.

Thermal Degradation Thresholds During Feed Pelleting at 85°C

At premix concentrations above 50 g/kg, dust control rather than flow becomes the primary occupational cleanability issue, because the API is finely spray-dried and electrostatically active. A medicated premix is prepared at 100 g/kg API on a pre-sieved corn-cob carrier with 1.5 % w/w soybean oil to control dust; mixing in a 400 L ribbon blender at 25 rpm for 20 min gives a coefficient of variation below 5.0 % for total anthraquinones. Granules are produced by top-spray fluid-bed granulation using a 5 % w/w povidone K30 binder solution at spray rate 120 g/min and inlet air 60 °C; the granulate is dried to 2.0 % water and screened to 0.5–1.0 mm. During feed pelleting at 85 °C for 90 s at 12 % moisture, baicalin retention remains in the range 92–96 % only when premix pH is kept at 6.5–7.0; acidification to pH 5.0 accelerates glucuronide hydrolysis and retention falls below 80 %. Published data for this exact multi-herb premix are limited; the quoted retention range is based on stress studies with baicalin and combined anthraquinones in feed matrices. Cross-contamination into the next batch must not exceed 1 % active substance per Regulation (EU) 2019/4; production lines therefore require a wash cycle with 20 kg wheat bran per 100 kg mixer capacity before release to non-medicated feed. The terminal products are a 100 g/kg medicated premix and a 50 g/kg granule for top-dress use in pigs.

Encapsulation of this API into hard gelatin capsules requires pre-blending with 0.5 wt% colloidal silicon dioxide if the angle of repose exceeds 38°; capsule presentations are otherwise rare in food-producing animals due to per-dose cost and manual dosing constraints.

If the Same API Is Delivered as an Oral Solution to Neonatal Ruminants, Buffer Selection Becomes the Control Variable

Because anthraquinone aglycones precipitate below pH 6.0, an oral solution prepared for neonatal calves requires a pH-stat range of 7.0–7.5 using a 20 mM sodium citrate buffer. The solution is compounded at 5.0 % w/v API, 15 % v/v propylene glycol, 0.45 % w/v trisodium citrate dihydrate, 0.1 % w/v sodium benzoate, and water to 100 %. Mixing is performed at 25–30 °C under vacuum to avoid air entrapment; the final bulk is filtered through a 10 µm polypropylene bag filter. The solution is filled into amber PET bottles; chemical and physical stability is maintained for 12 months at 25 °C/60 % RH when the pH is between 7.0 and 7.5. Below pH 6.0, total anthraquinone recovery falls below 85 % within 7 days; above pH 8.5, baicalin degradation products exceed 2 % at 30 days. Sodium benzoate is used at 0.1 % w/v because higher levels depress palatability in calves. After first opening, the solution is used within 14 days when stored below 25 °C. The solution is intended for oral drench administration and is released for deliverable mass per Ph. Eur. 2.9.27 and microbial quality per Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13.